Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Compugen Ltd. (CGEN)

0.702   -0.018 (-2.47%) 03-31 16:00
Open: 0.71 Pre. Close: 0.7198
High: 0.735 Low: 0.7
Volume: 80,333 Market Cap: 61(M)

Technical analysis

as of: 2023-03-31 4:17:32 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.95     One year: 1.05
Support: Support1: 0.68    Support2: 0.56
Resistance: Resistance1: 0.81    Resistance2: 0.89
Pivot: 0.72
Moving Average: MA(5): 0.71     MA(20): 0.74
MA(100): 0.85     MA(250): 1.29
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.3     %D(3): 22
RSI: RSI(14): 42.3
52-week: High: 3.25  Low: 0.5
Average Vol(K): 3-Month: 455 (K)  10-Days: 202 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CGEN ] has closed above bottom band by 25.8%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.74 - 0.74 0.74 - 0.74
Low: 0.69 - 0.69 0.69 - 0.7
Close: 0.71 - 0.72 0.72 - 0.73

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Headline News

Wed, 15 Mar 2023
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023 - Yahoo Finance

Sun, 12 Mar 2023
Silicon Valley Bank – The Aftermath. Which Companies Were ... - TipRanks

Sun, 12 Mar 2023
Israel stocks slip on SVB failure, government vows aid for tech firms - The Jerusalem Post

Thu, 09 Mar 2023
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 08 Mar 2023
Study Investigates Anti-TIGIT Therapy Plus Pembrolizumab in ... - Targeted Oncology

Mon, 06 Mar 2023
Compugen Doses First Patient in Triple Combination COM701 ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 87 (M)
Shares Float 80 (M)
% Held by Insiders 5.5 (%)
% Held by Institutions 19.8 (%)
Shares Short 2,090 (K)
Shares Short P.Month 1,870 (K)

Stock Financials

EPS -0.37
EPS Est Next Qtl -0.19
EPS Est This Year -0.74
EPS Est Next Year -0.83
Book Value (p.s.) 0.89
Profit Margin (%) 0
Operating Margin (%) -471.7
Return on Assets (ttm) -19.6
Return on Equity (ttm) -36.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.07
Sales Per Share 0.08
EBITDA (p.s.) -0.41
Qtrly Earnings Growth 0
Operating Cash Flow -35 (M)
Levered Free Cash Flow -19 (M)

Stock Valuations

PE Ratio -1.95
PEG Ratio 0
Price to Book value 0.78
Price to Sales 8.1
Price to Cash Flow -1.77

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.